Gateway Investment Advisers’s Teva Pharmaceutical Industries Limited TEVA Stock Holding History

Gateway Investment Advisers’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	–	Sell	-9,875	Closed	-$335K	–	878
2026 Q2	$335K	Buy	9,875 +121	+1%	+$4.03K	﹤0.01%	687
2026 Q1	$294K	Sell	9,754 -30,120	-76%	-$969K	﹤0.01%	615
2025 Q4	$1.24M	Buy	39,874 +29	+0.1%	+$714	0.01%	350
2025 Q3	$805K	Sell	39,845 -69,179	-63%	-$1.22M	0.01%	361
2025 Q2	$1.83M	Buy	109,024 +60,308	+124%	+$973K	0.02%	259
2025 Q1	$749K	Buy	48,716 +7,749	+19%	+$138K	0.01%	359
2024 Q4	$903K	Sell	40,967 -915	-2%	-$16.6K	0.01%	332
2024 Q3	$755K	Hold	41,882	–	–	0.01%	350
2024 Q2	$681K	Hold	41,882	–	–	0.01%	363
2024 Q1	$591K	Hold	41,882	–	–	0.01%	379
2023 Q4	$437K	Buy	41,882 +9,312	+29%	+$86.9K	0.01%	399
2023 Q3	$332K	Buy	+32,570	New	+$303K	﹤0.01%	417

Other funds holding TEVA

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

HWAM

Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return

IFM Investors Melbourne, Australia $16B AUM 33.69% 1-Year Est. Return

Y-Intercept (HK) Hong Kong $4.52B AUM 6.6% 1-Year Est. Return

Continental Advisors Park City, Utah $233M AUM 14.5% 1-Year Est. Return

Davenport & Co Richmond, Virginia $19.9B AUM 12.67% 1-Year Est. Return

GIA

GHP Investment Advisors Denver, Colorado $2.68B AUM 19.3% 1-Year Est. Return

Atria Investments Charlotte, North Carolina $10.3B AUM 19.62% 1-Year Est. Return

ASR Vermogensbeheer Utrecht, Netherlands $10.1B AUM 30.4% 1-Year Est. Return

RWA

Redhawk Wealth Advisors Minneapolis, Minnesota $987M AUM 25.25% 1-Year Est. Return

Gateway Investment Advisers's TEVA Position: Q3 2026 in Review

Gateway Investment Advisers sold out of Teva Pharmaceutical Industries Limited (TEVA) in Q3 2026, closing a stake of 9,875 shares — an estimated $335K sold.

Gateway Investment Advisers first reported a position in TEVA in Q3 2023 and held it in 12 quarters. The position peaked at $1.83M in Q2 2025. 43 funds tracked by Wall St. Rank hold TEVA as of Q3 2026.

Gateway Investment Advisers reported no remaining Teva Pharmaceutical Industries Limited position as of Q3 2026 after selling out during the quarter.
Gateway Investment Advisers sold 9,875 Teva Pharmaceutical Industries Limited shares in Q3 2026, an estimated $335K.
Gateway Investment Advisers first reported a position in Teva Pharmaceutical Industries Limited in Q3 2023 and held it in 12 quarters.
Gateway Investment Advisers's Teva Pharmaceutical Industries Limited position peaked at $1.83M in Q2 2025.
43 funds tracked by Wall St. Rank held Teva Pharmaceutical Industries Limited as of Q3 2026.

Based on Gateway Investment Advisers's 13F filing for Q3 2026, filed 13 Oct 2026.